Dynavax Technologies (NASDAQ:DVAX) Shares Up 13.3% - What's Next?

Shares of Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report) rose 13.3% during trading on Friday . The stock traded as high as $13.67 and last traded at $13.62. Approximately 203,784 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 2,093,019 shares. The stock had previously closed at $12.02.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DVAX. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday.

Dynavax Technologies Trading Up 8.2 %

The firm's 50-day simple moving average is $11.16 and its 200 day simple moving average is $11.24. The firm has a market cap of $1.70 billion, a P/E ratio of 118.28 and a beta of 1.34. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The business had revenue of $73.80 million for the quarter, compared to the consensus estimate of $76.92 million. During the same quarter in the prior year, the business earned $0.03 earnings per share. As a group, analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Dynavax Technologies by 1.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 1,172 shares during the period. SummerHaven Investment Management LLC grew its stake in Dynavax Technologies by 2.4% during the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company's stock valued at $617,000 after acquiring an additional 1,303 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in Dynavax Technologies by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company's stock valued at $1,404,000 after acquiring an additional 1,467 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 1,685 shares in the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.